Cabergoline

Drug Profile

Cabergoline

Alternative Names: Cabaser; CG 101; Dostinex; FCE 21336; PNU 142799

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Pfizer
  • Developer Kissei Pharmaceutical
  • Class Antiparkinsonians; Ergolines; Small molecules
  • Mechanism of Action Dopamine D2 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Marketed Galactorrhoea; Hyperprolactinaemia; Parkinson's disease
  • Discontinued Breast cancer; Pituitary cancer; Restless legs syndrome

Most Recent Events

  • 15 Dec 2016 Biomarkers information updated
  • 28 Feb 2014 Endo Health Solutions and Paladin Labs combine to form Endo International
  • 13 Sep 2004 A study has been added to the adverse events and Parkinson's disease therapeutic trials sections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top